Clinical Trial Update: A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

This is a Phase Ib dose-escalation trial evaluating intratumoral administration of IRS-1 HSV C134 in patients with recurrent malignant glioma, including gliobla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• IRS-1 HSV C134

Snippet

Sponsor: James Markert, MD | Conditions: Glioblastoma, Glioblastoma (GBM) | Phase 1 | Status: ACTIVE_NOT_RECRUITING